Clinical trials: Dual Antiplatelet Therapy
Ischemic Stroke, TIA
A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA
The REAl-life study on short-term Dual Antiplatelet treatment in Patients with ischemic stroke or Transient ischemic attack (READAPT) is an observational, multicenter, prospective study involving Italian centers.
- Trial name
- READAPT (NCT05476081)
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 127 sites in Italy
- Volunteers
- 2,239 people
- Sponsor
- University of L'Aquila
Restenosis
The ITALIC Study: Is There A LIfe for Drug-eluting Stents (DES) After Discontinuation of Clopidogrel
Background Drug-eluting stents (DES) have been extremely successful in reducing restenosis and the need for repeat revascularization procedures in patients who undergo PCI.
- Trial name
- ITALIC (NCT00780156)
- Where
- France
- Volunteers
- 1,235 people
- Sponsor
- French Cardiology Society
Myocardial Infarction Type 2
Effect of Classic Secondary Prevention in Type 2 MI: A Target Trial Emulation Study
A classic heart attack is caused by a blockage to the coronary arteries that supplies the heart muscle with oxygenated blood. The medical term for this condition is type 1 myocardial infarction.
- Trial name
- NCT06736353
- Testing
- Beta Blocker Therapy or No Therapy (Control), RAAS blocker Therapy or No therapy (Control), Statin Therapy or No Therapy (Control)
- Where
- Sweden
- Volunteers
- 14,000 people
- Sponsor
- Uppsala University
Coronary Artery Disease
EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events
EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and…
- Trial name
- EDUCATE (NCT01069003)
- Testing
- Thienopyridine Therapy, Surveillance Arm
- Where
- United States
- Volunteers
- 2,272 people
- Sponsor
- Medtronic Vascular
Ischemic Stroke, CYP2C19 Polymorphism
Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke
The goal of this observational study is to use a genetic test to help doctors prescribe the most effective medications after a patient has a stroke. One type of stroke is caused by a blood clot in brain vessels.
- Trial name
- ORCA-AIS (NCT06292117)
- Testing
- CYP2C19 Genotype
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- University of Virginia
Lacunar Stroke, Stroke
Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial
The goal of this clinical trial is to learn if a combination of antiplatelet drugs works better than intravenous tissue plasminogen activator to treat small ischemic stroke (lacunar stroke).
- Conditions
- Lacunar Stroke, Stroke, Ischemic Stroke
- Trial name
- LACUNAR-tPA (NCT07111559)
- Testing
- rt-PA, DAPT
- Where
- 29 sites in Japan
- Volunteers
- 500 people
- Sponsor
- Nippon Medical School
Non-ST Segment Elevation Myocardial Infarction
Anfibatide Phase Ib-IIa Clinical Trial
Investigate the safety and efficacy of Anfibatide in non-ST segment myocardial infarction patients
- Trial name
- NCT01585259
- Testing
- Anfibatide
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Lee's Pharmaceutical Limited
Intracranial Aneurysm, Aneurysm
Coated Mongolian Aneurysm Treatment Study 1
The purpose of this study is to assess safety and effectiveness of the p64 MW HPC or p48 MW HPC Flow Modulation Device under Dual Antiplatelet Medication.
- Conditions
- Intracranial Aneurysm, Aneurysm, Vascular Diseases
- Trial name
- COMATS 1 (NCT04305626)
- Testing
- Endovascular treatment of intracranial aneurysms
- Where
- Mongolia
- Volunteers
- 90 people
- Sponsor
- Phenox GmbH
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
The purpose of this study is to assess the the 1-year rates of ischemic and bleeding complications in patients whose dual antiplatelet therapy regimen post-PCI has been determined with the use of a clinical algorithm that…
- Conditions
- Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin, Clopidogrel
- Trial name
- TRIAGE (NCT01582217)
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronary Artery Disease, Percutaneous Coronary Intervention
The xDAPT External Validation Study
Dual antiplatelet therapy (DAPT) is routinely recommended after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation to prevent thrombotic complications.
- Trial name
- xDAPT (NCT06736626)
- Testing
- Percutaneous coronary intervention
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Carotid Artery Diseases
Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients
The optimal duration of dual antiplatelet therapy (DAPT) after carotid artery stenting (CAS) in patients at high bleeding risk (HBR) has not been established in randomized controlled trials.
- Trial name
- NCT06276374
- Testing
- Intervention 1(DAPT): Drug: Aspirin 100mg + Clopidogrel 75mg. Intervention 2(SAPT): Drug: Asprin 100mg or Clopidogrel 75mg
- Where
- South Korea
- Volunteers
- 1,556 people
- Sponsor
- Woo-Keun Seo
Coronary Artery Disease
Ticagrelore Alone Post PCI
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in…
- Trial name
- TICALONE (NCT06509893)
- Testing
- aspirin 80 mg and clopidogrel 75 mg daily, Ticagrelor 90 MG
- Where
- 2 sites in Iran
- Volunteers
- 5,400 people
- Sponsor
- Shiraz University of Medical Sciences
Stable Angina
Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy
Thanks to rapid reendothelialization derived from the pro-healing property of the EPC capture stent, 1-month dual antiplatelet therapy (DAPT) is recommended after EPC capture stent implantation.
- Trial name
- INNOVATION (NCT01394848)
- Testing
- Endothelial cell capture stent with 1 month clopidogrel, Everolimus eluting stent with 12 month clopidogrel, Atorvastatin 20mg loading
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Yonsei University
Cardiovascular Diseases, Interventional Cardiology
Repetitive Assessement of PRECISE-DAPT Score
Patients treated with percutaneous coronary intervention (PCI) require dual antiplatelet therapy (DAPT). Preliminary assessment of the PRECISE-DAPT score is mandatory in order to assess the risk of bleeding while on DAPT.
- Trial name
- RE-SCORE (NCT03848572)
- Testing
- Repetitive assessment of PRECISE-DAPT score
- Where
- 2 sites in Italy
- Volunteers
- 500 people
- Sponsor
- University of Roma La Sapienza
Myocardial Infarction, Acute
Cilostazol and Endothelial Progenitor Cell
To assess impact of adjunctive cilostazol on endothelial progenitor cell (EPC) mobilization in patients with acute myocardial infarction (To reveal the role of cilostazol in up-regulation of EPC count)
- Trial name
- EPISODE (NCT04407312)
- Testing
- Cilostazol Tablets, Aspirin, Clopidogrel
- Volunteers
- 60 people
- Sponsor
- Gyeongsang National University Hospital
Coronary Artery Disease
Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa)
Statin interference has been suggested among the mechanisms of reduction of the antiplatelet effect of clopidogrel. The purpose of this study is to evaluate pharmacodynamic effects of rosuvastatin and atorvastatin on platelet…
- Trial name
- gRANADa (NCT02030054)
- Testing
- Atorvastatin, Rosuvastatin
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- University of Roma La Sapienza
Acute Coronary Syndrome
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study
The purpose of this study is to explore the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after percutaneous…
- Trial name
- STOPDAPT-3 (NCT04609111)
- Testing
- No aspirin, 1-month DAPT
- Where
- Japan
- Volunteers
- 6,002 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Cardiovascular Disease, Coronary Artery Disease
Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention
Balloon angioplasty (Percutaneous Coronary Intervention (PCI)) is commonly used to treat patients with obstructive coronary artery disease (CAD).
- Trial name
- X-PLORER (NCT01442792)
- Testing
- UFH, Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban (Xarelto, BAY59-7939) and UFH
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 108 people
- Sponsor
- Bayer
Acute Coronary Syndrome, Myocardial Infarction
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
The optimal antithrombotic management in patients with coronary artery disease (CAD) and concomitant atrial fibrillation (AF) is unknown.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation, Atrial Flutter
- Trial name
- WOEST-3 (NCT04436978)
- Testing
- 30-day DAPT, Guideline-directed therapy
- Where
- 20 sites in Belgium, Netherlands
- Volunteers
- 2,000 people
- Sponsor
- St. Antonius Hospital
Ischemic Stroke, Transient Ischemic Attack
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
The goal of this clinical trial is to learn if zastaprazan can help prevent upper gastrointestinal bleeding in adults who have recently had a transient ischemic attack (TIA) or ischemic stroke and are taking antiplatelet or…
- Trial name
- NCT07730840
- Testing
- Zastaprazan
- Where
- 15 sites in South Korea
- Volunteers
- 984 people
- Sponsor
- Asan Medical Center